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Natriuretic peptide receptors mediate different responses in rat
renal microvessels
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Natriuretic peptide receptors mediate different responses in rat renal
microvessels. Atrial natriuretic peptide (ANP) has unique effects on the
renal vasculature, in that it dilates preglomerular vessels and constricts
efferent arterioles. In the present study we aimed to characterize the
natriuretic peptide receptor (NPR) subtypes, which mediate the renovas-
cular effects of ANP, using in vivo microscopy in the split hydroncphrotic
kidney model of rats. ANP (10 and 3 10), which binds to NPR-A and
NPR-C, dilated preglomerular vessels and constricted efferent arterioles
similarly to that found in previous studies. C-type natriuretic peptide (1O-
to 1O), which binds to NPR-B and NPR-C, dilated pre- and postglo-
merular vessels and profoundly increased glomerular blood flow. A
specific ligand of NPR-C, C-ANP (des-[Gln'8,Ser16,Gly20,Leu2t,
Gly22]ANP423-NH2, i0 to 10) was devoid of vascular effects. The
ANP antagonist A71915 (10 to 10—6) induced moderate dilation in renal
vessels possibly due to some agonistic activity on NPR-B. ANP-induced
preglomerular vasodilation was attenuated by A71915 (10—6) to 36 6%
of the initial response, whereas efferent vasoconstriction was completely
abolished (—4 4% of initial response). Our results indicate that ANP
dilates preglomerular vessels and constricts efferent arterioles through
NPR-A, both responses being antagonized by A71915 with different
potencies. Furthermore, our data show that in the rat renal microcircula-
tion stimulation of NPR-B results in vasodilation only, whereas NPR-C
does not mediate vascular responses.
Since the discovery of atrial natriuretic peptide (ANP) in 1981
[1], it has been shown that inhibition of tubular sodium reabsorp-
tion and an increase in glomerular filtration rate are involved in
the natriuresis induced by this hormone [2]. The increase in
glomerular filtration rate is due to an increase in glomerular
filtration pressure [3]. This increase in pressure is the result of
preglomerular vasodilation and efferent arteriolar constriction,
both of which are mediated by ANP [4, 5]. Currently, three
subtypes of natriuretic peptide receptors (NPR) are known [6, 71.
Most of the biological effects are thought to be mediated via
NPR-A and NPR-B, which possess intrinsic guanylyl cylase activ-
ity [8], while NPR-C was proposed to serve mainly as a clearance
receptor [91. ANP administration results in vasodilation, a de-
crease in blood pressure, and natriuresis. These responses have
been attributed to stimulation of NPR-A, the high affinity binding
site of ANP [10], and the subsequent increase in intracellular
Key words: atrial natriurctic peptidc, natriuretic peptide receptor, vaso-
dilation, rcnovascular effects.
Received for publication September 6, 1996
and in revised form February 21, 1997
Accepted for publication February 24, 1997
© 1997 by the International Society of Nephrology
cGMP [2]. In contrast to this understanding of the preglomerular
response, it is unclear by which receptor and mechanism ANP
induces constriction in the efferent arteriole [11].
The important role of ANP gene products in extracellular
volume regulation has recently been underlined by the observa-
tion of salt-sensitive hypertension in mice with a disruption of the
proANP gene [121. However, disruption of the NPR-A gene in
mice leads to chronic elevation of blood pressure, which is
unexpectedly not influenced by salt intake [13]. This finding
suggests that receptors other than NPR-A are involved in the
natriuretic action of ANP. In addition, a class of ANP antagonists
was developed by von Geldern and coworkers, which antagonized
the natriuretic effects but not the vasorelaxant and hypotensive
effects of ANP [14]. The aim of our present study was therefore to
characterize the NPR subtypes involved in the ANP-induced renal
vascular responses. As a model for the renal microcirculation we
used the split hydronephrotic rat kidney [151, which exhibits a
comparable vascular response to ANP [4, 11] as in the normal rat
kidney [3, 5]. In the absence of systemic side effects, we examined
the local, vascular effects of the ANP antagonist A71915 [14], and
of ANP, C-type natriuretic peptide (CNP) and C-ANP, which are
specific ligands for NPR-A, NPR-B and NPR-C, respectively [9,
10].
METHODS
Preparation of the hydronephrotic kidney
Experiments were performed on female Wistar rats (body wt
258 30 g, mean SD) in accordance with official guidelines for
animal protection. The technique of splitting the rat kidney has
been previously described in detail [15]. In brief, ligation of the
ureter via a flank incision was performed during pentobarbital
sodium anesthesia (Nembutal® 60 mg kg i.p.; Ceva, Bad
Segeherg, Germany). The final experiments were performed
under thiobutabarbital anesthesia (mactin® 100 mg kg' i.p.;
Byk Gulden, Konstanz, Germany) about three months after
induction of hydronephrosis. Body temperature was maintained at
37.0 to 37.5°C via a heating table, systemic blood pressure was
monitored via a cannula in the left femoral artery, and isotonic
saline (3 ml hr 1) was continuously infused via a cannula placed
in the jugular vein. After exposure of the left hydronephroptic
kidney by a flank incision, the kidney was split along the greater
curvature with a thermal cautery. The ventral half of the kidney
was sutured to a semicircular wire frame that was attached to the
bottom of a plexiglass bath. The entry of the renal hilus into the
bath was sealed with silicone grease, and the bath was filled with
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Fig. 1. Percent changes of renal vascular
diameters and of GBF in response to ANP (A),
CNP (B), and C.ANP (C). Symbols in A are:() 10; (•) 3 i0 ANP (N = 5). Symbols
in B are: (L) iOu; () 108; (•) i0 CNP(N = 5). In C, symbols are: (LII) i0; ()10—;(•) 10 C-ANP (N = 3). Data are means
SEM. *P < 0.05 versus control. Abbreviations
are: arc, arcuate artery; ilob, interlobular artery;
aff, afferent arteriole; eff, efferent arteriole; p,
proximal; d, distal.
an isotonic, isocolloidal solution (Haemaccel®; Behringwerke,
MarburglLahn, Germany) maintained at 37°C. A Leitz Ultropak
water immersion objective (UO-55) was combined with a televi-
sion and video recording system for in vivo transillumination
microscopy. Kidney preparations were allowed to equilibrate in
the tissue bath for at least one hour after the surgical procedure.
The microcirculatory parameters of this preparation have been
demonstrated to be stable for more than three hours [161.
Measurements
Renal vascular segments. Vessels were identified according to
their branching pattern from a selected glomerulus. Lumen
diameters of the following vascular segments were measured
(abbreviations serve for identification in Figs. 1 and 2): proximal
arcuate artery, near the interlobar artery (arc, p); distal arcuate
artery, near the interlobular artery (arc, d); proximal interlobular
artery, near the areuate artery (ilob, p); distal interlobular artery,
near the afferent arteriole (ilob, d); proximal afferent arteriole,
near the interlobular artery (aff, p); distal afferent arteriole, at the
narrowest segment before entering the glomerulus (aff, d); prox-
imal efferent arteriole, within 50 m of the glomerulus (eff, p);
distal efferent arteriole, near the first branching point (eff, d).
Glomerular blood flow (GBF). Red blood cell velocity was
determined in the efferent arteriole by a velocity tracking corre-
lator (Model 102B; 1PM Inc., San Diego, CA, USA) [171. To
obtain GBF, the measured red cell velocity was multiplied by the
luminal cross section of the efferent arteriole and corrected for
the Fahraeus effect [18].
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Experimental protocol
Each protocol started with two control periods separated by 10
minutes. Each protocol was made up of several periods, at the end
of which systemic blood pressure, GBF, and vascular diameters
were measured. All drugs were given into the kidney tissue bath.
Series I (N = 5), ANP and A 71915 + ANP. ANP (kindly
provided by W.-G. Forssmann, Lower Saxony Institute for Pep-
tide Research, Hannover, Germany) was applied in two concen-
trations (10 and 3 10—p) each for 15 minutes. Thereafter, ANP
was washed out by exchanging the tissue bath three times in 10
minute intervals. Hydronephrotic kidneys were then exposed to
increasing concentrations (10 , 10_8, 10 , and 10—6) of the
ANP antagonist A71915 [14] (kindly provided by Abbott Labora-
tories, Abbott Park, IL, USA) in 15 minute periods. In the
presence of 10' A71915, ANP was added with the same protocol
as at the beginning. Measurements were performed at the end of
each 15 minute period and after washout.
Series 2 (N = 3), A 71915 + AN?. The last control measurement
was followed by application of A71915 and subsequent addition of
ANP with the same protocol as in series 1.
Series 3 (N = 5), CNP. Increasing concentrations (10 iO,
and 10) of CNP1 22 (Bachem, Heidelberg, Germany) were given
into the tissue bath. Kidneys were exposed to each concentration
for 15 minutes. Measurements were done at the end of each 15
minute period.
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Fig. 2. Percent changes of renal vascular
diameters and of GBF in response to the ANP
antagonist A71915 (A) and to ANP in the
absence or presence of A71915 (B). Symbols
are: () 10_6 A71915 (N = 8); 3 10 ANP in
the absence (U) or presence (LI) of 10-6
A71915 (N = 5). Data are means SEM of
percent changes versus control (hatched and
filled columns) or versus 10-6 A71915 (open
columns), *j) < 0.05 versus control (hatched
and filled columns) or versus 106 A71915
(open columns), °P < 0.05 significant
attenuation of ANP response by A71915.
Series 4 (N = 3), C-ANP. C-ANP (des-[Gln18,Ser19,Gly20,
Leu2' ,G1y22]ANP423-NH2; Sigma, Deisenhofen, Germany), a
specific ligand for NPR-C [9], was applied in increasing concen-
trations (10, 10—8, and 10) with the same protocol as in series
3.
Data analysis
All values are presented as mean SEM. Changes in vascular
diameters and GBF are expressed as percentage changes from the
last control values unless otherwise stated. Analysis of variance,
the Bonferroni method for multiple comparisons, and paired and
unpaired t-tests were used as appropriate to test for statistical
significance. The overall significance level was set to P < 0.05.
RESULTS
The control values of vessel diameters, GBF, blood pressure,
and body wt are summarized in Table 1. Blood pressure did not
significantly change in any series of experiments.
ANP. ANP, which binds to NPR-A and NPR-C, concentration-
dependently dilated preglomerular vessels and constricted effer-
ent arterioles (Fig. 1A). The maximal dilation at 3 iO ANP was
observed in distal interlobular arteries (12 2%) and proximal
afferent arterioles (11 1%); the maximal constriction was
located in the proximal part of the efferent arteriole (Ii 1%).
Due to rather equal but opposite effects of ANP on pre- and
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Table 1. Control values of vessel lumen diameters, GBF, blood pressure, and body weight
Series 1
(N=5)
Series 2
(N=3)
Series 3
(N=5)
Series 4
(N=3)
Arcuate artery
Interlobular artery
Afferent arteriole
Efferent arteriole
proximal
distal
proximal
distal
proximal
distal
proximal
distal
m
jrm
j.m
m
m
jtm
sm
jrm
59.2 8.3
44.0 3.0
21.8 1.4
14.8 2.3
11.1 ii 1.5
9.1 1.4
15.5 2.4
18.4 1.1
69.9 5.2
48.5 2.6
24.0 2.2
14.3 0.9
10.5 0.5
7.1 1.7
14.3 1.8
19.2 3.9
58.5 9.6
39.2 7.0
21.5 2.3
12.7 3.3
9.3 1.4
7.5 1.9
15.2 4.8
20.4 3.2
56.3 9.0
39.0 5.6
23.9 3.7
12.9 3.6
9.3 1.2
7.7 0.5
15.0 2.3
20.3 2.4
GBFnlmin'
BloodpressuremmHg
Body weight g
79±5
112±5
272 19
55±21
110±5
253 42
37±21
108±10
254 35
27±10
105±5
243 6
Data are means SD.
postglomerular vessels, the increase in GBF was scant (14 2%
at 3 10). After the washout of ANP, all parameters returned to
baseline.
CNP. CNP, which binds to NPR-B and NPR-C, concentration-
dependently dilated renal vessels and increased GBF (Fig. 1B).
Vasodilation and GBF increase were already significant at 10
CNP. Maximal dilation at i0 CNP was observed in distal
interlobular arteries (12 2%) and proximal afferent arterioles
(13 2%). Efferent arteriolar dilation was less pronounced in
response to CNP (about 5% at 10—v). Pre- and postglomeruiar
dilation resulted in a clear increase in GBF (55 17% at 10—v).
C-ANP. Local application of C-ANP (10-° up to 10), a
specific ligand of NPR-C, did not significantly affect diameters of
preglomerular vessels and efferent arterioles (Fig. IC). GBF
remained unchanged.
A 71915 and ANP. The ANP antagonist A71915 induced iden-
tical dilation of renal vessels, irrespective of whether A71915 was
given directly after the control measurements (series 2) or after
the washout of ANP (series 1). The results of A71915 obtained in
series I and 2 were therefore pooled together (N = 8; Fig. 2A).
The dilation in some vessels and the GBF increase became
already significant at 10 A71915 (data not shown). At 106,
A71915 significantly dilated all preglomerular vessels (3 to 10%).
In the efferent arteriole, A71915 had no effects on the distal part
and induced slight dilation in the proximal part.
A71915 (10—6) significantly antagonized the effects of ANP in
series 1 (Fig. 2B). In the presence of A71915, ANP-induced (3
i0) preglomerular dilation was attenuated to 36 6% of the
initial response. ANP-induced constriction of the efferent arte-
riole was completely abolished by A71915 (—4 4% of the initial
response, P < 0.001 vs. preglomerular attenuation). In series 2,
the effects of ANP in the presence of A71915 did not differ from
those in series 1.
DISCUSSION
ANP induced preglomerular vasodilation and constriction in
efferent arterioles in a concentration-dependent manner similar
as in our previous studies (4, 11]. These unique effects of ANP on
the renal vasculature, which have also been demonstrated in rat
isolated afferent and efferent arterioles [5] and at the whole-
kidney level by micropuncture in the normal rat kidney [3j,
mediate the increase in GFR and thus contribute to ANP-induced
natriuresis [2]. At nanomolar concentrations, ANP binds to
NPR-A and NPR-C only [101. Since the NPR-C ligand C-ANP
was devoid of vascular effects, preglomerular vasodilation was
likely to be caused via NPR-A. Consistent with our finding,
Ardaillou and coworkers showed in cultured vascular smooth
muscle cells from the rabbit renal cortex, that ANP increases
cGMP also via NPR-A with a threshold concentration of 10
[191, which is in the range of normal circulating ANP concentra-
tions of 1 to 5.10_lI [21. However, it has to be mentioned that
several reports seriously question the role of cGMP in ANP-
induced vasodilation [20].
In contrast to preglomerular vasodilation, the mechanism of
efferent arteriolar constriction in response to ANP is poorly
understood. Since both CNP and C-ANP failed to constrict
efferent arterioles, NPR-B and NPR-C appear not to be involved
in ANP-induced constriction in our experiments. Furthermore,
the ability of A71915 to antagonize the effects of ANP on both
preglomerular vessels and efferent arterioles indicates that ANP
induced efferent vasoconstriction via binding to NPR-A. In a
previous study, urodilatin-induced efferent vasoconstriction was
abolished after bradykinin B2 or endothelin ETB receptor
blockade, and was enhanced after nitric oxide synthase inhibition
[111. Since urodilatin and ANP share similar NPR binding prop-
erties, the present results could imply that stimulation of (endo-
thelial?) NPR-A decreases local bradykinin, and increases local
endothelin and nitric oxide concentrations. However, the actual
mechanism of the interaction between NPR-A stimulation and
these autacoids remains unclear.
A7 1915 belongs to a class of compounds, which were developed
to inhibit ANP-induced cGMP production with weak intrinsic
stimulation in bovine transformed aortic endothelial cells and in
rat aortic vascular smooth muscle cells [14]. 10 A71915 caused
a 2.8-log shift in the ANP dose-response curve in these assays and
inhibited cGMP production with a pA2 value of 9.2 in a neuro-
blastoma ccli line that exclusively contains NPR-A [21]. In our
experiments A71915 itself caused distinct vasodilation, the pattern
of which was similar to that of CNP and could therefore reflect
some agonistic activity of A71915 at NPR-B. Similar vasodilating
properties have been reported for A74186, which was examined in
more detail as a representative compound of this class of antag-
onists [14]. A74186 relaxed rabbit aortic rings in vitro and de-
creased blood pressure in the rat in vivo.
Though A71915 completely blocked ANP-induced efferent
vasoconstriction, preglomerular vasodilation was only partially
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antagonized. Due to the intrinsic vasodilating properties of
A71915 in preglomerular vessels, A71915 might even be a weaker
antagonist for ANP-induced vasodilation as it is suggested by our
results, since ANP-induced vasodilation is diminished unspecifi-
cally after reduction of vascular tone by vasodilators [11]. Similar
to our results, A74186 hardly antagonized ANP-induced hypoten-
sion in vivo, whereas it abolished ANP-induced natriuresis [14].
The existence of distinct ANP receptors for mediating vasorelax-
ation and natriuresis has been proposed to explain the salt-
insensitive hypertension in NPR-A knock-out mice [13]. In addi-
tion, different mechanisms for the effects of ANP on pre- and
postglomerular vessels were suggested by our previous finding,
showing that pre- and postglomerular vascular effects of ANP are
differently modulated by vasoactive hormones [ii].
CNP, besides binding to NPR-C, is a specific ligand for NPR-B
at the concentrations we used [10]. CNP relaxed preconstricted
rat aorta by virtue of binding to N PR-B [22]. In our experiments,
CNP induced overall vasodilation indicating the presence of
NPR-B in renal vessels. Binding studies in isolated preglomerular
vessels of rats, however, failed to detect NPR-B [23]. On the other
hand, the presence of NPR-B mRNA in the renal vasculature has
been confirmed by polymerase chain reaction [241. Presently,
renal blood flow in response to CNP has been measured only in
dogs [25]. In this study, CNP neither affected renal blood flow nor
renal sodium excretion. However, currently available data on
CNP suggest that the renal effects may be species-dependent,
since CNP was antinatriuretic in another study on dogs [26],
whereas it induced natriuresis in the sheep and in the rat at
comparable doses [27, 28].
C-ANP has been introduced as a specific ligand for NPR-C [9].
Using C-ANP, it has been shown that NPR-C mainly serves as a
clearance receptor accepting all natriuretic peptides with high
affinity [9, 10]. In our experiments, C-ANP was devoid of vascular
effects at concentrations, which have been reported to saturate
NPR-C in renal vessels [23]. Thus, our results support the concept
of a biologically silent NPR-C. In agreement with our finding,
C-ANP did also not affect vascular resistance and GFR in the
isolated perfused rat kidney [9]. Blockade of NPR-C in vivo
diminishes the clearance of circulating natriuretic peptides, result-
ing in cardiovascular effects that are similar to those in response
to exogenous ANP application [9]. However, local application of
C-ANP in the hydronephrotic kidney blocks only a small fraction
of totally available NPR-C in the animal. Therefore, local appli-
cation of C-ANP should not affect the clearance and the levels of
natriuretic peptides, which is consistent with our results.
In addition to the concept of NPR-C as a clearance receptor,
there are several reports suggesting that NPR-C could also
mediate biological effects [20, 29-31]. In almost all of these
studies, C-ANP behaved as an agonist for the NPR-C-mcdiated
effects [29—31]. In one study, however, C-ANP antagonized
NPR-C-mediated antiproliferative effects on smooth muscle cells
[32]. Moreover, it has been proposed that C-ANP binding sites
might represent a heterogeneous receptor population [23, 311. In
a study using isolated rat glomeruli, one NPR-C population
internalized ANP corresponding to the clearance receptor,
whereas another population of N PR-C mediated a decrease in
cAMP [311. Since A71915 also contains the peptide sequence,
Arg11, lie'2, Asp'3, Arg'4, lIe'5, which is the minimal structural
requirement for NPR-C binding [7], we cannot exclude, however,
the remote possibility that ANP constricts efferent arterioles via a
subclass of NPR-C, on which both A71915 and C-ANP act as
antagonists and which is a low affinity binding site for CNP at the
same time.
In the present study we used the split hydronephrotic kidney, an
established model for the rat renal microcirculation [33]. Besides
obvious alterations—the hydronephrotic kidney is a non-filtering
kidney devoid of tubular structures—kidney-specific vascular re-
sponses are well preserved in this model, in particular for ANP
[34]. Furthermore, local application of NPR ligands permitted to
assess their renal vascular effects in the absence of otherwise
substantial systemic effects.
In summary, our results show that NPR-A and NPR-B mediate
renal vascular responses in the rat, while the gross function of
NPR-C is consistent with the concept of a clearance receptor on
renal vessels. While stimulation of N PR-B resulted in vasodilation
only, NPR-A appears to mediate both preglomerular vasodilation
and efferent arteriolar constriction in response to ANP. The ANP
antagonist A71915 antagonized pre- and postglomerular effects of
ANP, however, with different potencies.
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